Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988967544> ?p ?o ?g. }
- W1988967544 endingPage "608" @default.
- W1988967544 startingPage "602" @default.
- W1988967544 abstract "Pexa-Vec (pexastimogene devacirepvec, JX-594) is an oncolytic and immunotherapeutic vaccinia virus designed to destroy cancer cells through viral lysis and induction of granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven tumor-specific immunity. Pexa-Vec has undergone phase 1 and 2 testing alone and in combination with other therapies in adult patients, via both intratumoral and intravenous administration routes. We sought to determine the safety of intratumoral administration in pediatric patients. In a dose-escalation study using either 106 or 107 plaque-forming units per kilogram, we performed one-time injections in up to three tumor sites in five pediatric patients and two injections in one patient. Ages at study entry ranged from 4 to 21 years, and their cancer diagnoses included neuroblastoma, hepatocellular carcinoma, and Ewing sarcoma. All toxicities were ≤ grade 3. The most common side effects were sinus fever and sinus tachycardia. All three patients at the higher dose developed asymptomatic grade 1 treatment-related skin pustules that resolved within 3–4 weeks. One patient showed imaging evidence suggestive of antitumor biological activity. The two patients tested for cellular immunoreactivity to vaccinia antigens showed strong responses. Overall, our study suggests Pexa-Vec is safe to administer to pediatric patients by intratumoral administration and could be studied further in this patient population. Pexa-Vec (pexastimogene devacirepvec, JX-594) is an oncolytic and immunotherapeutic vaccinia virus designed to destroy cancer cells through viral lysis and induction of granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven tumor-specific immunity. Pexa-Vec has undergone phase 1 and 2 testing alone and in combination with other therapies in adult patients, via both intratumoral and intravenous administration routes. We sought to determine the safety of intratumoral administration in pediatric patients. In a dose-escalation study using either 106 or 107 plaque-forming units per kilogram, we performed one-time injections in up to three tumor sites in five pediatric patients and two injections in one patient. Ages at study entry ranged from 4 to 21 years, and their cancer diagnoses included neuroblastoma, hepatocellular carcinoma, and Ewing sarcoma. All toxicities were ≤ grade 3. The most common side effects were sinus fever and sinus tachycardia. All three patients at the higher dose developed asymptomatic grade 1 treatment-related skin pustules that resolved within 3–4 weeks. One patient showed imaging evidence suggestive of antitumor biological activity. The two patients tested for cellular immunoreactivity to vaccinia antigens showed strong responses. Overall, our study suggests Pexa-Vec is safe to administer to pediatric patients by intratumoral administration and could be studied further in this patient population." @default.
- W1988967544 created "2016-06-24" @default.
- W1988967544 creator A5017070005 @default.
- W1988967544 creator A5017250643 @default.
- W1988967544 creator A5019082757 @default.
- W1988967544 creator A5025236828 @default.
- W1988967544 creator A5033267651 @default.
- W1988967544 creator A5041658971 @default.
- W1988967544 creator A5043573924 @default.
- W1988967544 creator A5044195657 @default.
- W1988967544 creator A5052820259 @default.
- W1988967544 creator A5054250864 @default.
- W1988967544 creator A5057196933 @default.
- W1988967544 creator A5066566375 @default.
- W1988967544 creator A5070358157 @default.
- W1988967544 creator A5074724246 @default.
- W1988967544 creator A5082232276 @default.
- W1988967544 date "2015-03-01" @default.
- W1988967544 modified "2023-10-15" @default.
- W1988967544 title "Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients" @default.
- W1988967544 cites W1525386479 @default.
- W1988967544 cites W1965497380 @default.
- W1988967544 cites W2011535108 @default.
- W1988967544 cites W2020518300 @default.
- W1988967544 cites W2026577436 @default.
- W1988967544 cites W2042765773 @default.
- W1988967544 cites W2057672138 @default.
- W1988967544 cites W2066857625 @default.
- W1988967544 cites W2090732350 @default.
- W1988967544 cites W2093059993 @default.
- W1988967544 cites W2100538647 @default.
- W1988967544 cites W2101058247 @default.
- W1988967544 cites W2108883303 @default.
- W1988967544 cites W2144999788 @default.
- W1988967544 cites W2150701651 @default.
- W1988967544 cites W2158897346 @default.
- W1988967544 cites W2165652424 @default.
- W1988967544 cites W2167451108 @default.
- W1988967544 cites W2169881433 @default.
- W1988967544 doi "https://doi.org/10.1038/mt.2014.243" @default.
- W1988967544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4351466" @default.
- W1988967544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25531693" @default.
- W1988967544 hasPublicationYear "2015" @default.
- W1988967544 type Work @default.
- W1988967544 sameAs 1988967544 @default.
- W1988967544 citedByCount "122" @default.
- W1988967544 countsByYear W19889675442015 @default.
- W1988967544 countsByYear W19889675442016 @default.
- W1988967544 countsByYear W19889675442017 @default.
- W1988967544 countsByYear W19889675442018 @default.
- W1988967544 countsByYear W19889675442019 @default.
- W1988967544 countsByYear W19889675442020 @default.
- W1988967544 countsByYear W19889675442021 @default.
- W1988967544 countsByYear W19889675442022 @default.
- W1988967544 countsByYear W19889675442023 @default.
- W1988967544 crossrefType "journal-article" @default.
- W1988967544 hasAuthorship W1988967544A5017070005 @default.
- W1988967544 hasAuthorship W1988967544A5017250643 @default.
- W1988967544 hasAuthorship W1988967544A5019082757 @default.
- W1988967544 hasAuthorship W1988967544A5025236828 @default.
- W1988967544 hasAuthorship W1988967544A5033267651 @default.
- W1988967544 hasAuthorship W1988967544A5041658971 @default.
- W1988967544 hasAuthorship W1988967544A5043573924 @default.
- W1988967544 hasAuthorship W1988967544A5044195657 @default.
- W1988967544 hasAuthorship W1988967544A5052820259 @default.
- W1988967544 hasAuthorship W1988967544A5054250864 @default.
- W1988967544 hasAuthorship W1988967544A5057196933 @default.
- W1988967544 hasAuthorship W1988967544A5066566375 @default.
- W1988967544 hasAuthorship W1988967544A5070358157 @default.
- W1988967544 hasAuthorship W1988967544A5074724246 @default.
- W1988967544 hasAuthorship W1988967544A5082232276 @default.
- W1988967544 hasBestOaLocation W19889675441 @default.
- W1988967544 hasConcept C104317684 @default.
- W1988967544 hasConcept C121608353 @default.
- W1988967544 hasConcept C126322002 @default.
- W1988967544 hasConcept C203014093 @default.
- W1988967544 hasConcept C2522874641 @default.
- W1988967544 hasConcept C2776715637 @default.
- W1988967544 hasConcept C2781356689 @default.
- W1988967544 hasConcept C2993561819 @default.
- W1988967544 hasConcept C40767141 @default.
- W1988967544 hasConcept C502942594 @default.
- W1988967544 hasConcept C54355233 @default.
- W1988967544 hasConcept C55493867 @default.
- W1988967544 hasConcept C71924100 @default.
- W1988967544 hasConcept C81885089 @default.
- W1988967544 hasConcept C82210918 @default.
- W1988967544 hasConcept C86803240 @default.
- W1988967544 hasConceptScore W1988967544C104317684 @default.
- W1988967544 hasConceptScore W1988967544C121608353 @default.
- W1988967544 hasConceptScore W1988967544C126322002 @default.
- W1988967544 hasConceptScore W1988967544C203014093 @default.
- W1988967544 hasConceptScore W1988967544C2522874641 @default.
- W1988967544 hasConceptScore W1988967544C2776715637 @default.
- W1988967544 hasConceptScore W1988967544C2781356689 @default.
- W1988967544 hasConceptScore W1988967544C2993561819 @default.
- W1988967544 hasConceptScore W1988967544C40767141 @default.
- W1988967544 hasConceptScore W1988967544C502942594 @default.